January 31, 2018 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing

New system launch planned for second half of 2018 with two CE-IVD molecular diagnostics, U.S. launch planned for 2019 and broad pipeline in development Germantown, Maryland, and Hilden, Germany, January 31, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire STAT-Dx, a privately-held company developing... Read more

January 31, 2018 M&A, Partnerships PR/Corporate

QIAGEN reports results for fourth quarter and full-year 2017, announces STAT-Dx acquisition and new $200 million share repurchase

Solid Q4 results as QIAGEN achieves full-year 2017 targets: Q4 2017: Net sales $396.9 million ( 8% actual, 5% CER); adjusted net sales rise 6% CER excluding portfolio changes vs. 5-6% CER guidance  Q4 2017: EPS -$0.18 including impact of predominantly non-cash U.S. tax reform charge; adjusted EPS $0.43 ($0.43 CER) vs. ~$0.41-42 CER guidance... Read more